✨ Free AI Report
BIOCRYST PHARMACEUTICALS INC: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research BIOCRYST PHARMACEUTICALS INC
Company Research

BIOCRYST PHARMACEUTICALS INC: Business Overview, Financials & Competitive Analysis

BIOCRYST PHARMACEUTICALS INC is a leading biotechnology company dedicated to designing, optimizing, and delivering novel medicines that address the unmet medical needs of patients with rare and...

Analyst-debate audio for BIOCRYST PHARMACEUTICALS INC

AskCyborg analysts argue the bull and bear cases for BIOCRYST PHARMACEUTICALS INC across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Company OverviewProduct PortfolioLeadership and Management TeamFinancial Overview of BIOCRYST PHARMACEUTICALS INCMarketing StrategiesMarket Overview and Competitors
Get Interactive Report Freeor start reading below
Live on AskCyborg
7/10Strong
BioCryst Pharmaceuticals, Inc.

BioCryst has a Buy consensus rating from 12 analysts as of January 22, 2026, with strong revenue growth momentum offset by leverage concerns.

▶︎ Listen to the 90-second analyst debate
7/ 10Strong

Cyborg Score thesis

BioCryst has a Buy consensus rating from 12 analysts as of January 22, 2026, with strong revenue growth momentum offset by...

Read the full analyst-debate transcript →
Industry Biotechnology - Rare Disease Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: August 17, 2026
AI-Verified Research
30+ Page Report

Get the Latest BIOCRYST PHARMACEUTICALS INC Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

BIOCRYST PHARMACEUTICALS INC is a leading biotechnology company dedicated to designing, optimizing, and delivering novel medicines that address the unmet medical needs of patients with rare and serious diseases. Founded in 1986, BIOCRYST PHARMACEUTICALS INC has grown to become a prominent player in the biopharmaceutical industry, known for its innovative approach to drug development and a strong commitment to improving patient lives.

Company Overview

Pro stress-test →

Headquartered in Durham, North Carolina, BIOCRYST PHARMACEUTICALS INC has carved out a niche in the biotechnology sector by focusing on the discovery, research, and development of small molecule medicines. The company’s mission is to bring life-changing therapies to patients suffering from rare diseases, leveraging its proprietary structure-guided drug design technology.

Product Portfolio

Pro stress-test →

BIOCRYST PHARMACEUTICALS INC’s product portfolio includes several groundbreaking treatments:

  • Orladeyo® (berotralstat): An oral therapy for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older.
  • Rapivab® (peramivir): An intravenous drug for the treatment of acute uncomplicated influenza in patients who are 2 years and older.
  • BCX9930: An oral Factor D inhibitor in development for the treatment of complement-mediated diseases.
  • Galidesivir: An investigational antiviral drug with activity against a broad range of viruses, including coronaviruses, filoviruses, and paramyxoviruses.

Leadership and Management Team

Pro stress-test →

BIOCRYST PHARMACEUTICALS INC boasts a seasoned leadership team with extensive experience in the biotech and pharmaceutical industries:

  • Jon P. Stonehouse: CEO and President, bringing over 25 years of experience in the pharmaceutical industry.
  • Anthony Doyle: Chief Financial Officer, with a strong background in financial management and strategic planning.
  • Helen Thackray, M.D.: Chief Research and Development Officer, responsible for overseeing the company’s R&D activities.
  • Alane Barnes: Chief Legal Officer, handling all legal and regulatory affairs.

Financial Overview of BIOCRYST PHARMACEUTICALS INC

The company has demonstrated robust financial performance, with significant revenue growth driven by the successful launch of Orladeyo® and Rapivab®. Key financial metrics include:

  • Revenue: Consistent year-over-year growth, with a focus on expanding market reach for existing products.
  • R&D Investment: Significant investment in research and development to drive innovation and pipeline expansion.
  • Net Income: Positive net income reflecting operational efficiencies and strong product performance.

Marketing Strategies

BIOCRYST PHARMACEUTICALS INC employs a multifaceted marketing approach to promote its products:

  • Direct-to-Consumer Marketing: Leveraging digital channels and patient advocacy groups to raise awareness and educate patients about their therapies.
  • Physician Outreach: Engaging healthcare professionals through targeted campaigns, educational initiatives, and conferences.
  • Global Expansion: Collaborating with international partners to extend the reach of their products in key markets worldwide.

Market Overview and Competitors

BIOCRYST PHARMACEUTICALS INC operates in a highly competitive market, with key competitors including:

  • Takeda Pharmaceuticals: A major player in the rare disease space, offering treatments for HAE and other conditions.
  • CSL Behring: Known for its portfolio of therapies for rare and serious diseases.
  • Vertex Pharmaceuticals: A leader in developing treatments for cystic fibrosis and other genetic disorders.

Sales Strategies

The company employs several sales strategies to drive growth:

  • Specialty Pharmacies: Partnering with specialty pharmacies to ensure patients have access to their medications.
  • Field Sales Force: Deploying a dedicated sales team to engage with healthcare providers and promote their products.
  • Digital Sales Channels: Utilizing digital platforms to reach a broader audience and facilitate product distribution.

Technologies Utilized

BIOCRYST PHARMACEUTICALS INC leverages advanced technologies to support its research and development efforts:

  • Structure-Guided Drug Design: Utilizing computational modeling to design and optimize small molecule compounds.
  • High-Throughput Screening: Employing automated systems to rapidly identify potential drug candidates.
  • Clinical Trial Platforms: Utilizing digital platforms to streamline clinical trial processes and data management.

HR Practices

The company is committed to creating a positive work environment for its employees:

  • Employee Development: Offering training and development programs to support employee growth and career advancement.
  • Diversity and Inclusion: Promoting a diverse and inclusive workplace culture.
  • Work-Life Balance: Implementing flexible work arrangements and wellness programs to support employee well-being.

Corporate Responsibility

BIOCRYST PHARMACEUTICALS INC is dedicated to corporate social responsibility:

  • Patient Advocacy: Partnering with patient advocacy groups to support patients and raise awareness about rare diseases.
  • Environmental Sustainability: Implementing sustainable practices to minimize environmental impact.
  • Community Engagement: Supporting local communities through charitable initiatives and volunteer programs.

Future Plans

BIOCRYST PHARMACEUTICALS INC has ambitious plans for the future:

  • Pipeline Expansion: Continuing to advance their pipeline of innovative therapies for rare diseases.
  • Global Growth: Expanding their presence in international markets through strategic partnerships and collaborations.
  • Innovation: Investing in cutting-edge technologies to drive innovation and enhance their R&D capabilities.

For a more detailed and comprehensive analysis of BIOCRYST PHARMACEUTICALS INC, including in-depth company insights, financial data, and market trends, subscribe to our full report available at AskCyborg.com. Our report provides valuable information for investors, industry professionals, and anyone interested in the biopharmaceutical sector.


Get the detailed report on BIOCRYST PHARMACEUTICALS INC by subscribing

What the analysts stress-tested

The top findings that survived the multi-agent debate for BIOCRYST PHARMACEUTICALS INC.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when BIOCRYST PHARMACEUTICALS INC has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Lanadelumab (Takhzyro)Plasma kallikrein inhibitor for HAEDanicopan (Fabhalta)Factor D inhibitor for rare complement-mediated diseasesC1-inhibitor (Berinert)Traditional HAE therapy

Compare BIOCRYST PHARMACEUTICALS INC with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

BIOCRYST PHARMACEUTICALS INC operates in Biotechnology - Rare Disease Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Rare Disease Therapeutics research →
NEW · MCP server

Ask your AI assistant about BIOCRYST PHARMACEUTICALS INC

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare BIOCRYST PHARMACEUTICALS INC and its top competitor on Cyborg Score”
“What did BIOCRYST PHARMACEUTICALS INC do this quarter?”
“Is BIOCRYST PHARMACEUTICALS INC a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does BIOCRYST PHARMACEUTICALS INC do?+
BIOCRYST PHARMACEUTICALS INC is a leading biotechnology company dedicated to designing, optimizing, and delivering novel medicines that address the unmet medical needs of patients with rare and...
What is BIOCRYST PHARMACEUTICALS INC's Cyborg Score?+
BIOCRYST PHARMACEUTICALS INC has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are BIOCRYST PHARMACEUTICALS INC's main competitors?+
Named competitors include Lanadelumab (Takhzyro), Danicopan (Fabhalta), C1-inhibitor (Berinert). The full competitive landscape is in the AskCyborg report.
How can I get the full BIOCRYST PHARMACEUTICALS INC research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the BIOCRYST PHARMACEUTICALS INC research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track BIOCRYST PHARMACEUTICALS INC over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Company Research

Gambling and Lotteries Industry BriefingStationery and Office Products Industry BriefingDefense Tech Industry BriefingAi Infrastructure Systems Industry BriefingPet Insurance Industry BriefingSelf-Storage Industry BriefingMetal Additive Manufacturing Industry BriefingAi Accelerator Hardware Systems Industry BriefingLuxury Wines & Spirits Industry BriefingEnzymatic Plastic Recycling Industry BriefingInfrastructure as a Service (IaaS) Industry Briefingluxury fashion apparel Industry Briefing

Explore Industry Research

Travel Insurance Industry Company Research ReportSecurity Services Industry Company Research ReportLandscaping and Grounds Maintenance Industry Company Research ReportJanitorial and Cleaning Services Industry Company Research ReportSustainability Consulting Industry Company Research ReportReal Estate Investment Trusts (REITs) Industry Company Research Report
Browse All Company ResearchBrowse All Industry ResearchRSS Feed